Dr. Yan Leyfman, MD, has been recognized as one of the top international researchers in oncology by ASH and ASCO. During the COVID-19 pandemic, he was recruited as the Director of the Immunology Division of the Global COVID-19 Taskforce, which produced one of the first mechanisms for SARS-CoV-2 and COVI-Flu along with therapeutic interventions for both. In 2021, Dr. Leyfman presented the first mechanism to explain the interplay between cancer and COVID-19 at the 2021 ASCO Annual Meeting. His work has been published as the cover article in the journal, Shock, and in the textbook, Insights on a Post-COVID World.
Title : Severe SARS-CoV-2 & Cancer: Unlocking the immunology with promising therapeutic interventions
Title : Stem Cell Therapies: A promising approach to tackle COVID-19 in Cancer patients